Endovascular Treatment of TASC C and D Femoropopliteal Arterial Disease With Heparin-Bonded Covered Stents: The Impact of Distal Run-Off Vessels

Abstract

Introduction:

In the last 2 decades, several studies in the literature evaluated the possible role of covered stents in the treatment of TransAtlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions but, despite the encouraging results, the employment of these devices was never included in clinical guidelines. The aim of this study is to evaluate the role of the technical aspects in patients with TASC C or D lesions that were treated with the GORE VIABAHN endoprosthesis and to elaborate a computerized method to objectively estimate the post-stent run-off and predict stent-graft failure.

Materials and Methods:

In this monocentric retrospective study, we collected the patients who were treated in our department from December 2014 to May 2021. Inclusion criteria comprised: (1) patients who underwent endovascular treatment of a TASC C or D femoropopliteal lesions using one or more heparin-bonded covered stent(s) and (2) clinical follow-up >2 years. Exclusion criteria were clinical follow-up <2 years or missing. An in-house computerized analysis to estimate the post-stent run-off, CEVERO (Computerized Estimation of VEssel Run-Off), was elaborated.

Results:

Sixty-six patients were enrolled in the study. Eleven patients had a TASC type C lesion, and 55 patients presented a type D lesion. The median follow-up time was 2.6 years. Twenty-nine patients (43.9%) experienced a major adverse limb event. Primary patency after 6, 12 and 24 months was 74.2%, 60.6%, and 57.6%; primary-assisted patency was 78.8%, 65.2%, and 59.1%. The presence of <2 run-off vessels (p<0.001) was correlated with stent-graft failure. The CEVERO analysis demonstrated an accuracy of 90.0% in predicting stent-graft failure.

Conclusions:

The treatment of TASC C and D femoropopliteal lesions remains technically challenging. Our study supported the hypothesis that run-off is the most critical factor in determining the outcome of the procedure and that concomitant angioplasty of the tibial vessels might improve the patency of the covered stent. The CEVERO analysis could permit a real-time, objective estimation of the distal run-off using conventional angiographic images, and it might be employed as a tool in the intraprocedural decision-making process, but its clinical applicability should be evaluated on external validation cohorts.

Clinical Impact

The endovascular treatment of TASC C and D femoropopliteal lesions is technically challenging and run-off seems to be the most critical factor in determining the outcome. Concurrent angioplasty of the tibial vessels can create adequate run-off to avoid stent failure. The CEVERO analysis is a computerized estimation of run-off that might be a useful tool in the decision-making process.

Keywords

chronic limb-threatening ischemia endovascular intervention covered stent endoprosthesis computer-aided diagnosis

Get full access to this article

View all access options for this article.

References

Farber

Chronic limb-threatening ischemia. N Engl J Med. 2018;379:171–180.

Farber

Eberhardt

RT.

The current state of critical limb ischemia: a systematic review. JAMA Surg. 2016;151:1070–1077.

Hardman

Jazaeri

Smith

Gupta

Overview of classification systems in peripheral artery disease. Semin Intervent Radiol. 2014;31(4):378–388.

Jebran

Popov

Zenker

, et al. Is there an alternative to the surgical above-knee bypass in treatment of superficial femoral artery disease? experiences with Viabahn stent graft. Vasc Endovascular Surg. 2013;47(7):502–506.

Reijnen

MMPJ

van Walraven

Fritschy

, et al. 1-year results of a multicenter randomized controlled trial comparing heparin-bonded endoluminal to femoropopliteal bypass. JACC Cardiovasc Interv. 2017;10:2320–2331.

Laird

Katzen

Scheinert

, et al. Nitinol stent implantation vs. Balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19(1):1–9.

Hajibandeh

Antoniou

Torella

Antoniou

GA.

Covered vs uncovered stents for aortoiliac and femoropopliteal arterial disease: a systematic review and meta-analysis. J Endovasc Ther. 2016;23(3):442–452.

Lammer

Zeller

Hausegger

, et al. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial. Cardiovasc Intervent Radiol. 2015;38:25–32.

Ichihashi

Takahara

Yamaoka

, et al. Drug eluting versus covered stent for femoropopliteal artery lesions: results of the ULTIMATE study. Eur J Vasc Endovasc Surg. 2022;64(4):359–366.

10.

Mohr

Oyama

Luu

Stinis

CT.

Clinical outcomes of endovascular treatment of TASC-II C and D femoropopliteal lesions with the Viabahn endoprosthesis. Cardiovasc Revasc Med. 2015;16(8):465–468.

11.

Böhme

Noory

Brechtel

, et al. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: 36-month results of the Viabahn 25 cm trial. J Endovasc Ther. 2021;28(2):222–228.

12.

Saxon

Chervu

Jones

, et al. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. J Vasc Interv Radiol. 2013;24(2):165–173; quiz 174.

13.

Kruse

Poelmann

Doomernik

, et al. Five-year outcome of self-expanding covered stents for superficial femoral artery occlusive disease and an analysis of factors predicting failure. J Endovasc Ther. 2015;22(6):855–861.

14.

Iida

Ohki

Soga

, et al. Twelve-month outcomes from the Japanese post-market surveillance study of the Viabahn endoprosthesis as treatment for symptomatic peripheral arterial disease in the superficial femoral arteries. J Endovasc Ther. 2022;29(6):855–865.

15.

Ohki

Kichikawa

Yokoi

, et al. Long-term results of the Japanese multicenter Viabahn trial of heparin bonded endovascular stent grafts for long and complex lesions in the superficial femoral artery. J Vasc Surg. 2021;74(6):1958–1967.

16.

Filippiadis

Binkert

Pellerin

, et al. CIRSE quality assurance document and standards for classification of complications: the CIRSE classification system. Cardiovasc Intervent Radiol. 2017;40(8):1141–1146.

17.

Okuno

Iida

Shiraki

, et al. Impact of calcification on clinical outcomes after endovascular therapy for superficial femoral artery disease: assessment using the peripheral artery calcification scoring system. J Endovasc Ther. 2016;23(5):731–737.

18.

TASC Steering Committee; Jaff

White

Hiatt

, et al.An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II). J Endovasc Ther. 2015;22:663–677.

19.

Konstas

Goldmakher

Lee

T-Y

Lev

MH.

Theoretic basis and technical implementations of CT perfusion in acute ischemic stroke, part 1: theoretic basis. AJNR Am J Neuroradiol. 2009;30:662–668.

20.

Verta

Schneider

Alonzo

Hahn

Percutaneous Viabahn-assisted subintimal recanalization for severe superficial femoral artery occlusive disease. J Vasc Interv Radiol. 2008;19:493–498.

21.

Zhang

Bao

Zhao

, et al. Effectiveness of Viabahn in the treatment of superficial femoral artery occlusive disease: a systematic review and meta-analysis. J Endovasc Ther. 2015;22(4):495–505.

22.

Rizzoni

Rosei

EA.

Small artery remodeling in diabetes mellitus. Nutr Metab Cardiovasc Dis. 2009;19:587–592.